Patient management issues in metastatic bone disease

Seminars in Oncology

Volumn 31, Issue SUPPL. 10, 2004, Pages 79-82

  Cameron, David ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE DISEASE; BONE METASTASIS; BONE PAIN; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG TOLERABILITY; FOLLOW UP; GASTROINTESTINAL DISEASE; HEALTH CARE; HUMAN; KIDNEY INJURY; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE;

ADMINISTRATION, ORAL; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; HUMANS; INFUSIONS, INTRAVENOUS;

EID: 5644266125     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.07.027     Document Type: Conference Paper

References (22)

1. R.E. Coleman Skeletal complications of malignancy Cancer 80 suppl 8 1997 1568 1594
2. C. Maxwell, R. Swift, M. Goode Advances in supportive care of patients with cancer and bone metastases nursing implications of zoledronic acid Clin J Oncol Nurs 7 2003 403 408
3. L. DesHarnais Castel, K. Bajwa, J.P. Markle A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease Support Care Cancer 9 2001 545 551
4. B.E. Hillner, J.N. Ingle, R.T. Chlebowski American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 2003 4042 4057
5. J.T. Chang, L. Green, J. Beitz Renal failure with the use of zoledronic acid N Engl J Med 349 2003 1676 1679
6. B.E. Hillner, J.C. Weeks, C.E. Desch Pamidronate in prevention of bone complications in metastatic breast cancer a cost-effectiveness analysis J Clin Oncol 18 2000 72 79
7. J.J. Body, I.J. Diel, M.R. Lichinitser Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 14 2003 1399 1405
8. R. Bell, I.J. Diel, J.J. Body Renal safety of ibandronate in patients with bone metastases from breast cancer phase III trial results Eur J Cancer Suppl 2 2004 132
9. J.J. Body, M. Lichinitzer, N. Andreeva Safety of an intravenous (i.v.) loading dose of ibandronate followed by daily oral dosing in metastatic bone disease results of an open-label study [abstract 735] Proc Am Soc Clin Oncol 23 2004 60
10. G. Neugebauer, W. Koehler, L. Akinkunmi Influence of peak ibandronic acid concentrations after 6 mg i.v. administration with shortened infusion time (15 and 30 minutes) on renal safety in man [abstract 486] Proc Am Soc Clin Oncol 20 2001 122A
11. G. Liu, E. Franssen, M.I. Fitch Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 1997 110 115
12. V.J. O'Neill, C.J. Twelves Oral cancer treatment developments in chemotherapy and beyond Br J Cancer 87 2002 933 937
13. J.J. Body, I.J. Diel, M. Lichinitzer Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease results from two randomised, placebo-controlled phase III studies Br J Cancer 90 2004 1133 1137
14. J.J. Body Effectiveness and cost of bisphosphonate therapy in tumor bone disease Cancer 97 3 2003 859 865
15. T. Delea, J. McKiernan, M. Liss Impact of skeletal complications on total medical care costs in breast cancer patients with bone metastases Bone 34 suppl 1 2004 S86
16. N.L. Liberato, M. Marchetti, G. Barosi Clinical and economic issues in the treatment of advanced breast cancer with bisphosphonates Drugs Aging 20 2003 631 642
17. E.V. McCloskey, J.F. Guest, J.A. Kanis The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma Drugs 61 2001 1253 1274
18. N.L. Liberato, M. Marchetti, A. Tamburlini Pamidronate in advanced breast cancer a cost-effectiveness analysis Eur J Cancer 36 suppl 3 2000 S4
19. W.A. Biermann, R.I. Cantor, F.M. Fellin An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone Bone 12 suppl 1 1991 S37 S42
20. E. Guignard, J. Dardenne, A. Pele Economic assessment of clodronate in the preventative treatment of bone resorption in patients with metastatic breast cancer Eur J Cancer 33 suppl 9 1997 25
21. N.J. Bruce, E.V. McCloskey, J.A. Kanis Economic impact of using clodronate in the management of patients with multiple myeloma Br J Haematol 104 1999 358 364
22. G. Dranitsaris, T. Hsu Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer Support Care Cancer 7 1999 271 279